SAN DIEGO, March 29 /PRNewswire/ -- Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of the intravenous (IV) dosage form of torezolid phosphate, an IV and orally administered second generation oxazolidinone for the treatment of serious gram positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). The trial achieved its primary goal of establishing the safety and tolerability of the 200 mg IV dose of torezolid phosphate to be used in Trius’ upcoming Phase 3 clinical trials. The study also demonstrated high oral bioavailability of torezolid phosphate. Trius believes that these results, coupled with data from the prior Phase 1 and Phase 2 clinical trials of the oral dosage form of torezolid phosphate, provide the clinical basis for Trius to proceed with its Phase 3 clinical trials planned for the second half of 2010.
